Diabesity Rounds

Weekly semaglutide lowered BMI in children aged 6 to under 12 with obesity: phase 3 trial

In a randomised, placebo-controlled trial in 167 children with obesity, weekly semaglutide reduced BMI by 13.5% at week 68, while BMI rose by 2.7% with placebo.

At a glance

  • At week 68, BMI fell by 13.5% with semaglutide and rose by 2.7% with placebo (difference -16.2 percentage points).
  • BMI category improved in 79% of children on semaglutide and 23% on placebo; 38% versus 2% moved below the obesity threshold.
  • Gastrointestinal adverse events were the most common and were more frequent with semaglutide; 1 child stopped treatment because of them.

Key result

Semaglutide lowered BMI by 13.5% vs a 2.7% rise with placebo at week 68.

Change in BMI from baseline, Week 68

semaglutide−13.5%
placebo2.7%

167 participants · P<0.001

Numbers as reported in the source.

This report in under a minute

53 seconds. Free to use in your CME talks, with credit to Diabesity Rounds. Download the video · captions (SRT).

The study

This was a phase 3, double-blind, randomised, placebo-controlled trial (STEP Young) published in The New England Journal of Medicine. It enrolled children aged 6 to under 12 years with obesity. The authors note that once-weekly subcutaneous semaglutide is approved for obesity in adolescents and adults, but data in young children have been lacking.

A total of 167 children were randomised in a 2:1 ratio: 112 to once-weekly subcutaneous semaglutide and 55 to placebo. Treatment lasted 104 weeks, followed by a 7-week washout with no study drug. Both groups received counselling on lifestyle change. The primary end point was the percent change in body-mass index (BMI) from baseline to week 68. The confirmatory secondary end point was a reduction in BMI category at week 68. The trial was funded by Novo Nordisk.

What they found

At week 68, mean BMI fell by 13.5% with semaglutide and rose by 2.7% with placebo. The estimated between-group difference was -16.2 percentage points (95% CI, -19.4 to -12.9; P<0.001).

At week 104, BMI had fallen by 9.4% with semaglutide and risen by 8.4% with placebo (between-group difference, -17.8 percentage points; 95% CI, -22.2 to -13.3).

At week 68, BMI category improved in 79% of children on semaglutide and in 23% on placebo (odds ratio, 7.8; 95% CI, 3.5 to 17.6; P<0.001). BMI was below the obesity threshold (the 95th percentile for age and sex) in 38% of the semaglutide group and in 2% of the placebo group.

Adverse events occurred in 96% of children on semaglutide and in 93% on placebo. Gastrointestinal adverse events were the most common and were more frequent with semaglutide. They led to stopping treatment in 1 child in the semaglutide group.

How much weight to give it

This is a phase 3, double-blind, randomised, placebo-controlled trial, which is a strong design. The authors conclude that 68 weeks of semaglutide gave a significantly greater mean percent reduction in BMI than placebo. Treatment also continued to week 104, which adds some information on durability while on the drug.

There are limits to keep in mind. The trial is modest in size, with 167 children. The main outcomes are BMI change and BMI category, not longer-term health outcomes. The abstract does not report what happened to BMI during the 7-week washout after stopping treatment. It also does not give details on growth, puberty, mental health or the types of gastrointestinal events. The trial was funded by Novo Nordisk. The full paper should be read for these details.

For your clinic

This trial gives randomised evidence on semaglutide in an age group where, as the authors note, data have been lacking. Both groups received lifestyle counselling, so the results show the effect of semaglutide on top of lifestyle support, not instead of it.

The abstract does not support decisions on dose, duration or what happens after stopping. Gastrointestinal side effects were common, and almost all children in both groups reported some adverse event. Read the full paper before drawing practical conclusions for young children.

Source

Semaglutide for the Treatment of Obesity in Children 6 to <12 Years of Age.

Jastreboff AM, Harder-Lauridsen NM, Van Name M et al.. The New England journal of medicine. 16 November 2026

Read the source · DOI 10.1056/NEJMoa2604058

Teaching a session? Download this report as a slide (PNG, free to use with credit).

For registered medical practitioners. This report summarises published research and is not advice for individual patients. Read the full paper and current guidelines before changing practice. Found an error? Write to editor@diabesityrounds.com; see our corrections and editorial policy.

More on glp-1 and incretin drugs

Go deeper